NIDA’s Division of Therapeutics and Medical Consequences is seeking capability statements from qualified small businesses under NAICS 541715 that can synthesize, acquire, analyze, store, and distribute controlled and uncontrolled drugs of abuse and related compounds, including stable and radioactive isotope-labeled materials. The work includes maintaining inventory and purity (at least 95%), re-purifying deteriorated compounds, updating chemical data sheets, managing the DISCS database, processing researcher requests, and providing secure storage and shipment. Vendors must be able to receive and store hundreds of DEA controlled and uncontrolled compounds, including peptides, in kilogram quantities, with refrigeration and secure solution storage as needed. Mandatory capability includes a DEA Research Registration for Schedules II–V and demonstrated ability to obtain Schedule I registration. This notice is for market research only, will not result in an award, and responses are not proposals or quotes.